A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

Inclusion Criteria:

- Female subjects at least 18 years of age, with a histologically confirmed diagnosis
of non-mucinous epithelial ovarian cancer (including fallopian tube and primary
peritoneal cancer) in first relapse after a first remission of 6 to 18 months
duration.

- Subjects must have undergone surgery. Subjects must have received primary
chemotherapy, including at least one platinum agent.

- Subject is eligible for retreatment with the same chemotherapy regimen that was used
to induce remission (Exception: may reduce the dose of or discontinue taxane if
contraindicated due to neurotoxicity.)

- CA125 must have been elevated prior to original chemotherapy.

- CA125 must be elevated at the time of relapse.

- Life expectancy greater than or equal to 6 months, as estimated by the investigator.

- Eastern Cooperative Oncology Group performance status of 0, 1 or 2

- Subjects must consent to use a medically acceptable method of contraception
throughout the study period and for 28 days after final MORAb-003 administration,
unless surgically sterile.

- Any significant concomitant medical conditions must be well controlled and stable in
the opinion of the investigator for at least 30 days prior to Study Day 1.

- Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows:

- Absolute neutrophil count (ANC) ≥ 1.2 x 10e9/L

- Platelet count ≥ 100 x 10e9/L

- Hemoglobin ≥ 8 g/dL

- Subject must be willing and able to provide written informed consent. Translations
of informed consent information may be provided, subject to the local institutional
review board's (IRB's) policy.

Exclusion Criteria:

- Known central nervous system (CNS) tumor involvement.

- Evidence of other active malignancy requiring treatment.

- Clinically significant heart disease (e.g., congestive heart failure of New York
Heart Association Class III or IV, angina not well controlled by medication, or
myocardial infarction within 6 months).

- Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Exception:
Subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal
supraventricular tachycardia [SVT], are eligible).

- Active serious systemic disease, including active bacterial or fungal infection.

- Active hepatitis or HIV infection.

- Treatment within three months with immunomodulatory therapy (e.g. interferons,
immunoglobulin therapy, interleukin 1 receptor antagonist [IL-1RA] or systemic
corticosteroids). Short term systemic corticosteroids or topical or intra-articular
steroids are acceptable, subject to the judgment of the investigator.

- Treatment with a monoclonal antibody therapy AND have evidence of an immune or
allergic reaction or documented HAHA.

- Maintenance of first remission by taxane or other chemotherapeutic agent(s).

- Initiation or planned initiation of cancer therapy not given to induce primary
remission. Substitutions of agents materially similar to those used in the original
regimen are permissible.

- Breast-feeding, pregnant, or likely to become pregnant during the study.